Q BioMed leverages strategic partnerships to assist companies in accessing public markets, facilitating the transition of biomedical startups from incubation to development. The firm aims to maximize risk-adjusted returns by concentrating on value-driven assets with mitigated risks and imminent valuation inflections. The company's pipeline products include Strontium89, QBM-001, UTTROSIDE-B, and MAN 01.
Cyborg Score Rationale
The company has a market capitalization of $14.5K with QBIO stock declining 100.0% over the past year. Q Biomed generated $284K in revenue over the trailing twelve months with a -1211.7% operating margin and -721.7% net profit margin. With a current ratio of 0.01, short-term liquidity bears monitoring.
Top Insights
Strontium89 treats pain from bone metastases caused by multiple primary tumors.
The company's pipeline includes a liver cancer drug adding significant value to the promise of that potential chemotherapeutic drug.
Last funding round closed on May 11, 2021 from a Post-IPO Equity round.
The company generated $1.9M in operating cash flow despite negative profitability margins.
Named Competitors
Scholar Rock — Biotech company in clinical stage development
Sunshine Biopharma — Biopharma company developing therapeutic assets
CNS Pharmaceuticals — Biomedical development company
Recent Developments
(June 2023) Provided shareholder update on strategic operational opportunities
(February 2023) Liver cancer drug candidate IP portfolio strengthened; Uttroside B received patent allowance
(July 2022) Q2 2022 revenue up 100% vs Q1 with Strontium89 sales showing uptick
Open the full interactive Q BioMed Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.